Trevi: Phase 2 CANAL interim p<0.0001 (52% cough reduction); PRISM enrollment done

Trevi Therapeutics, Inc.

Phase 2 CANAL interim analysis: 52% placebo-adjusted reduction in daytime cough events (p<0.0001); enrollment ended early; full data Q3 2022.
Phase 2b/3 PRISM trial (pruritus in prurigo nodularis) completed enrollment Jan 31, 2022; top-line data expected Q2 2022.
Q4 2021 net loss $8.5M vs $9.5M in Q4 2020; full-year net loss $33.9M vs $32.8M in 2020.
Cash and equivalents of $36.8M as of Dec 31, 2021.
KOL webinar on IPF chronic cough set for March 30, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.